ÂÜÀòÂÒÂ×

Stéphanie Val, PhD, RAC, is a distinguished professional in gene therapy and immunology with significant experience in cell process development and regulatory affairs. Currently serving as a Gene Therapy CMC Reviewer at the FDA since November 2023, Stéphanie previously held roles as Principal Scientist and Senior Scientist at TCR² Therapeutics Inc. and Children's National Health System, respectively, focusing on T cell therapy and GMP manufacturing. Stéphanie's research background includes leading projects in innate immunity and exosome biology, contributing to various publications and grants, and managing research teams. With a doctoral degree in Toxicology from Université Paris Cité, Stéphanie has extensive expertise in both toxicological and biological research, complemented by a strong record of collaboration and innovation in scientific research.